Truist Financial Corp Biomarin Pharmaceutical Inc Transaction History

Truist Financial Corp

$62.9 Billion
Q3 2024

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$83.81 - $99.0 $196,785 - $232,452	-2,348 Reduced 35.14%	4,333 $378,000
Q4 2023 Feb 02, 2024	BUY	$76.22 - $98.51 $81,326 - $105,110	1,067 Added 19.01%	6,681 $644,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $138,153 - $153,435	1,624 Added 40.7%	5,614 $496,000
Q2 2023 Aug 01, 2023	SELL	$86.68 - $100.3 $90,580 - $104,813	-1,045 Reduced 20.75%	3,990 $345,000
Q1 2023 May 05, 2023	BUY	$87.74 - $117.27 $46,853 - $62,622	534 Added 11.86%	5,035 $489,000
Q4 2022 Feb 17, 2023	BUY	$80.93 - $108.63 $36,256 - $48,666	448 Added 11.05%	4,501 $465,000
Q3 2022 Oct 26, 2022	BUY	$82.16 - $96.94 $19,882 - $23,459	242 Added 6.35%	4,053 $344,000
Q2 2022 Jul 22, 2022	SELL	$71.48 - $86.85 $59,113 - $71,824	-827 Reduced 17.83%	3,811 $316,000
Q1 2022 Apr 22, 2022	SELL	$74.28 - $92.69 $259,014 - $323,210	-3,487 Reduced 42.92%	4,638 $358,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $208,920 - $266,452	-2,913 Reduced 26.39%	8,125 $718,000
Q3 2021 Nov 05, 2021	BUY	$74.77 - $85.47 $186,027 - $212,649	2,488 Added 29.1%	11,038 $853,000
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $226,605 - $254,454	-3,001 Reduced 25.98%	8,550 $713,000
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $145,947 - $177,117	-1,953 Reduced 14.46%	11,551 $873,000
Q4 2020 Nov 19, 2021	SELL	$72.61 - $90.2 $7.56 Million - $9.4 Million	-104,185 Reduced 88.53%	13,504 $1.18 Million
Q4 2020 Feb 18, 2021	BUY	$72.61 - $90.2 $7.07 Million - $8.78 Million	97,357 Added 478.84%	117,689 $10.3 Million
Q3 2020 Nov 05, 2021	SELL	$71.87 - $131.03 $5.66 Million - $10.3 Million	-78,810 Reduced 79.49%	20,332 $1.55 Million
Q3 2020 Nov 13, 2020	SELL	$71.87 - $131.03 $300,775 - $548,360	-4,185 Reduced 4.05%	99,142 $7.54 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $622,956 - $972,766	-7,831 Reduced 7.04%	103,327 $12.7 Million
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $6.65 Million - $9.03 Million	93,218 Added 519.61%	111,158 $9.39 Million
Q4 2019 Nov 16, 2021	SELL	$64.27 - $86.37 $2.88 Million - $3.87 Million	-44,810 Reduced 71.41%	17,940 $1.52 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $3.29 Million - $4.43 Million	51,236 Added 444.99%	62,750 $5.31 Million
Q3 2019 Oct 31, 2019	SELL	$67.4 - $85.11 $69,017 - $87,152	-1,024 Reduced 8.17%	11,514 $776,000
Q2 2019 Jul 24, 2019	SELL	$80.35 - $93.9 $165,762 - $193,715	-2,063 Reduced 14.13%	12,538 $1.07 Million
Q1 2019 Apr 23, 2019	SELL	$84.2 - $98.62 $47,909 - $56,114	-569 Reduced 3.75%	14,601 $1.3 Million
Q4 2018 Jan 22, 2019	SELL	$80.14 - $106.07 $73,969 - $97,902	-923 Reduced 5.74%	15,170 $1.29 Million
Q3 2018 Oct 17, 2018	BUY	$93.92 - $105.72 $103,312 - $116,292	1,100 Added 7.34%	16,093 $1.56 Million
Q2 2018 Jul 26, 2018	BUY	$76.01 - $99.03 $4,712 - $6,139	62 Added 0.42%	14,993 $1.41 Million
Q1 2018 Apr 20, 2018	BUY	$77.67 - $92.63 $23,456 - $27,974	302 Added 2.06%	14,931 $1.21 Million
Q4 2017 Jan 29, 2018	BUY	$80.76 - $95.13 $1,292 - $1,522	16 Added 0.11%	14,629 $1.31 Million
Q3 2017 Oct 23, 2017	BUY	$80.6 - $94.95 $1.18 Million - $1.39 Million	14,613	14,613 $1.36 Million

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

Black Rock Inc. New York, NY

22.7M
Shares

$1.52 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19.3M
Shares

$1.28 Billion
0.02% of portfolio
Primecap Management CO Pasadena, CA

18.9M
Shares

$1.26 Billion
0.99% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$926 Million
0.59% of portfolio
Capital Research Global Investors Los Angeles, CA

10.5M
Shares

$699 Million
0.16% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.

Account